New data highlight promise of 2 Ebola treatments - CIDRAP
A research group today published full results from a clinical trial of four Ebola therapies in the Democratic Republic of the Congo (DRC) outbreak, in which preliminary findings in August led health officials to push the pause button to steer patients into groups to receive two treatments that stood out as most promising. An international research group, which includes renowned Ebola researcher and DRC health official Jean-Jacques Muyembe-Tamfum, MD, published its findings in the New England Journal of Medicine ( NEJM ). Study fleshes out preliminary findings In August, an independent board that was monitoring the study in people treated in DRC Ebola treatment units took an early look at the data and saw that mortality rates were significantly lower in those who received the monoclonal antibody cocktail REGN-EB3 (made by Regeneron of Tarrytown, New York) and the single monoclonal antibody mAb 114, developed from antibodies of an Ebola survivor. The other two therapies in the tria...